A Randomized, Placebo-controlled, Observer-blind, Phase 2 Study to Evaluate Safety and Immunogenicity of the Investigational M72/AS01E Mycobacterium Tuberculosis (Mtb) Vaccine in Virally Suppressed, Antiretroviral-treated Participants With Human Immunodeficiency Virus (HIV)
Latest Information Update: 15 Jun 2023
At a glance
- Drugs GSK 692342 (Primary) ; Adjuvants
- Indications Tuberculosis
- Focus Adverse reactions
- Acronyms MESA-TB
- 12 Jun 2023 Status changed from active, no longer recruiting to completed.
- 31 Jan 2022 Planned End Date changed from 1 Jul 2022 to 1 Aug 2022.
- 31 Jan 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Aug 2022.